Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABEO NASDAQ:MLTX NASDAQ:PHAR NASDAQ:QURE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABEOAbeona Therapeutics$6.00+2.8%$4.99$4.00▼$7.54$341.96M1.351.18 million shs655,611 shsMLTXMoonLake Immunotherapeutics$17.64+3.7%$17.51$5.95▼$62.75$1.27B1.011.70 million shs197,564 shsPHARPharming Group$16.24+0.4%$16.38$8.60▼$21.34$1.15B0.0423,564 shs2,175 shsQUREuniQure$22.06+4.2%$16.70$8.73▼$71.50$1.38B0.872.81 million shs764,569 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABEOAbeona Therapeutics+7.37%+8.77%+20.95%+14.76%-8.91%MLTXMoonLake Immunotherapeutics+1.67%+2.10%-2.02%+13.17%-59.40%PHARPharming Group-4.77%-1.52%-2.71%-4.21%+75.28%QUREuniQure+10.61%+17.23%+23.31%-20.60%+33.17%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABEOAbeona Therapeutics$6.00+2.8%$4.99$4.00▼$7.54$341.96M1.351.18 million shs655,611 shsMLTXMoonLake Immunotherapeutics$17.64+3.7%$17.51$5.95▼$62.75$1.27B1.011.70 million shs197,564 shsPHARPharming Group$16.24+0.4%$16.38$8.60▼$21.34$1.15B0.0423,564 shs2,175 shsQUREuniQure$22.06+4.2%$16.70$8.73▼$71.50$1.38B0.872.81 million shs764,569 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABEOAbeona Therapeutics+7.37%+8.77%+20.95%+14.76%-8.91%MLTXMoonLake Immunotherapeutics+1.67%+2.10%-2.02%+13.17%-59.40%PHARPharming Group-4.77%-1.52%-2.71%-4.21%+75.28%QUREuniQure+10.61%+17.23%+23.31%-20.60%+33.17%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABEOAbeona Therapeutics 2.60Moderate Buy$19.00216.93% UpsideMLTXMoonLake Immunotherapeutics 2.38Hold$23.0830.82% UpsidePHARPharming Group 2.60Moderate Buy$38.33136.04% UpsideQUREuniQure 2.53Moderate Buy$44.50101.77% UpsideCurrent Analyst Ratings BreakdownLatest ABEO, QURE, MLTX, and PHAR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2026QUREuniQure HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/5/2026QUREuniQure Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$28.004/30/2026QUREuniQure Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$31.00 ➝ $37.004/27/2026PHARPharming Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)4/20/2026QUREuniQure The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$9.00 ➝ $10.004/13/2026PHARPharming Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)4/10/2026PHARPharming Group Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold4/10/2026PHARPharming Group Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$37.003/30/2026PHARPharming Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)3/30/2026MLTXMoonLake Immunotherapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$30.003/24/2026PHARPharming Group HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$37.00(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABEOAbeona Therapeutics$5.82M58.59N/AN/A$2.94 per share2.04MLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/A$4.27 per shareN/APHARPharming Group$376.13M3.05$0.20 per share81.72$3.95 per share4.11QUREuniQure$16.10M86.40N/AN/A$3.19 per share6.91Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABEOAbeona Therapeutics$71.18M$1.035.8410.90N/AN/A-60.65%-40.78%5/13/2026 (Estimated)MLTXMoonLake Immunotherapeutics-$227.32M-$3.52N/AN/AN/AN/A-66.56%-50.23%5/11/2026 (Estimated)PHARPharming Group$2.85M$0.011,624.0036.91N/A0.71%1.08%0.59%5/7/2026 (Estimated)QUREuniQure-$198.97M-$3.45N/AN/AN/A-1,236.00%-174.03%-27.41%N/ALatest ABEO, QURE, MLTX, and PHAR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026ABEOAbeona Therapeutics-$0.34N/AN/AN/A$4.57 millionN/A5/11/2026Q1 2026MLTXMoonLake Immunotherapeutics-$0.91N/AN/AN/AN/AN/A5/7/2026Q1 2026PHARPharming Group$0.05N/AN/AN/A$92.06 millionN/A5/5/2026Q1 2026QUREuniQure-$0.88-$0.85+$0.03-$0.85$5.24 million$3.56 million3/17/2026Q4 2025ABEOAbeona Therapeutics-$0.35-$0.34+$0.01-$0.34$5.65 million$3.00 million3/12/2026Q4 2025PHARPharming Group$0.15$0.07-$0.08$0.07$111.76 million$106.50 million3/3/2026Q4 2025QUREuniQure-$0.93-$0.56+$0.37-$0.56$4.84 million$5.57 million2/25/2026Q4 2025MLTXMoonLake Immunotherapeutics-$0.92-$0.92N/A-$0.92N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABEOAbeona TherapeuticsN/AN/AN/AN/AN/AMLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/AN/APHARPharming GroupN/AN/AN/AN/AN/AQUREuniQureN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABEOAbeona Therapeutics0.056.936.74MLTXMoonLake Immunotherapeutics0.249.279.27PHARPharming Group0.332.592.03QUREuniQure0.2510.4310.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABEOAbeona Therapeutics80.56%MLTXMoonLake Immunotherapeutics93.85%PHARPharming Group0.03%QUREuniQure78.83%Insider OwnershipCompanyInsider OwnershipABEOAbeona Therapeutics5.40%MLTXMoonLake Immunotherapeutics12.05%PHARPharming Group2.07%QUREuniQure4.79%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABEOAbeona Therapeutics9056.88 million53.81 millionOptionableMLTXMoonLake Immunotherapeutics271.73 million63.09 millionOptionablePHARPharming Group28070.62 million69.16 millionNot OptionableQUREuniQure50063.07 million60.05 millionOptionableABEO, QURE, MLTX, and PHAR HeadlinesRecent News About These CompaniesUniQure plans U.K. AMT-130 MAA submission in Q3 as it expects cash runway into H2 2029May 5 at 8:58 PM | seekingalpha.comuniQure Q1 Earnings Call HighlightsMay 5 at 4:19 PM | marketbeat.comuniQure N.V. (QURE) Q1 2026 Earnings Call TranscriptMay 5 at 4:04 PM | seekingalpha.comuniQure (NASDAQ:QURE) Issues Quarterly Earnings ResultsMay 5 at 11:29 AM | marketbeat.comuniQure (QURE) Reports Q1 Loss, Misses Revenue EstimatesMay 5 at 9:26 AM | zacks.comUniQure: Q1 Earnings SnapshotMay 5 at 9:20 AM | chron.comuniQure Announces First Quarter 2026 Financial Results and Provides Recent Company UpdatesMay 5 at 7:05 AM | globenewswire.comHow The uniQure (QURE) Investment Story Is Shifting With AMT-130 And Regulatory UncertaintyMay 4 at 6:56 PM | finance.yahoo.comuniQure (NASDAQ:QURE) Shares Up 6.3% - Still a Buy?May 4 at 2:33 PM | marketbeat.comuniQure N.V. (NASDAQ:QURE) Receives $42.83 Consensus Price Target from AnalystsMay 4 at 6:08 AM | americanbankingnews.comuniQure’s AMT-130 Regulatory Progress Sharpens Huntington’s Disease Investment CaseMay 3 at 11:57 PM | finance.yahoo.comJennison Associates LLC Boosts Stake in uniQure N.V. $QUREMay 2, 2026 | marketbeat.comuniQure (QURE) Expected to Announce Quarterly Earnings on TuesdayMay 1, 2026 | americanbankingnews.comuniQure (QURE) Projected to Post Earnings on TuesdayMay 1, 2026 | marketbeat.comUniQure eyes UK approval for embattled Huntington’s gene therapy after FDA quarrelApril 30, 2026 | biospace.comBuniQure meets with UK MHRA on AMT-130 for Huntington’s diseaseApril 30, 2026 | thepharmaletter.comTUniQure, in ‘symbolic’ win, to seek UK approval of Huntington’s gene therapyApril 30, 2026 | finance.yahoo.comQURE stock just shot up 8% - uniQure’s much-talked-about Huntington’s disease therapy gets a UK boostApril 30, 2026 | msn.comUniQure rises after regulatory updates on gene therapyApril 30, 2026 | msn.comuniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington’s DiseaseApril 30, 2026 | markets.businessinsider.comuniQure (NASDAQ:QURE) Given New $37.00 Price Target at Chardan CapitalApril 30, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeABEO, QURE, MLTX, and PHAR Company DescriptionsAbeona Therapeutics NASDAQ:ABEO$6.00 +0.17 (+2.83%) As of 12:44 PM Eastern This is a fair market value price provided by Massive. Learn more.Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.MoonLake Immunotherapeutics NASDAQ:MLTX$17.64 +0.63 (+3.70%) As of 12:44 PM Eastern This is a fair market value price provided by Massive. Learn more.MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.Pharming Group NASDAQ:PHAR$16.24 +0.07 (+0.43%) As of 12:43 PM Eastern This is a fair market value price provided by Massive. Learn more.Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.uniQure NASDAQ:QURE$22.06 +0.90 (+4.23%) As of 12:45 PM Eastern This is a fair market value price provided by Massive. Learn more.uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Just How Big a Problem Could Amazon’s Cash Burn Rate Be? BlackBerry Rewrites Its Own Operating System Grab Holdings Faces Hurdles, But Upside Potential Is Hard to Ignore Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
